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Objectives: 1) To explore the utility of tuberculosis (TB)
symptom screening for symptoms of ⩾2 weeks’ duration
in a routine setting, and 2) to compare differences in TB
diagnosis between human immunodeficiency virus (HIV)
infected and non-HIV-infected pregnant women in western Kenya.
Design: Comparative cross-sectional study among pregnant women with known HIV status screened for TB from
2010 to 2012, in Eldoret, western Kenya.
Results: Of 2983 participants, respectively 34 (1%),
1488 (50.5%) and 1461 (49.5%) had unknown, positive
and negative HIV status. The median age was respectively
30 years (interquartile range [IQR] 26–35) and 26 years
(IQR 24–31) in HIV-infected and non-infected participants.
A positive symptom screen was found in respectively
8% (119/1488) and 5% (67/1461) of the HIV-infected
and non-infected women. The median CD4 count at enrolment was 377 cells/μl (IQR 244–530) for HIV-infected
women. One non-HIV-infected patient was sputumpositive. For HIV-infected women, TB was presumptively
treated in 1% (16/1488) based on clinical symptoms and
chest X-ray. Cumulatively, anti-tuberculosis treatment was
offered to 0.6% (17/2949) of the participants.
Conclusion: This study does not seem to demonstrate the
utility of TB symptom screening questionnaires in a routine setting among pregnant women, either HIV-infected
or non-infected, in western Kenya.

R

eduction of tuberculosis (TB) transmission, morbidity and mortality relies largely on intensiﬁed
case ﬁnding, with consequent early initiation of adequate treatment.1,2 This is particularly important
among pregnant women in resource-limited settings
where TB is a cause of non-obstetrical (indirect) maternal deaths.3,4 This burden is higher in settings with a
high prevalence of human immunodeﬁciency virus
(HIV) infection.5,6 Kenya has an adult HIV prevalence
of 6.2%,7 with an unacceptably high maternal mortality ratio of 488 per 100 000 live births; 25% of these
deaths are attributed to indirect causes such as TB,
anaemia, HIV and malaria.8
TB case notiﬁcation data are not stratiﬁed for pregnancy, but women of reproductive age bear a higher
burden of TB in sub-Saharan Africa than their male
counterparts.1,9 Data from Western Cape, South Africa,
indicate that there is a 24.2-fold higher incidence of
TB disease among infants born to HIV-infected mothers, diagnosed at a mean age of 6 months, than among
those of HIV-negative mothers.10 This suggests probable

underdiagnosis of active TB disease during the antenatal and postnatal periods. HIV and TB co-infection
during pregnancy have a multiplier effect on maternal
morbidity and mortality, and result in poorer pregnancy outcomes.1,11 In Pune, India, TB increased the
probability of death by 2.2-fold among HIV-infected
women who developed TB and by 3.4-fold for their infants compared to women who did not develop TB.11
In Johannesburg, South Africa, 70% of obstetric deaths
in HIV-infected women were mainly attributed to
TB.12 These ﬁgures suggest that routine screening of
pregnant women for TB in endemic settings would be
helpful, particularly those who are HIV-infected.
The World Health Organization (WHO) recommends ruling out active TB and identifying those in
need of further testing among HIV-infected adults using speciﬁc symptoms (current cough of any duration,
fever, weight loss or night sweats).13 Although these
recommendations were not speciﬁc for pregnancy,
Gupta et al. used this recommendation and found a
1.4% (11/799) prevalence of active TB among HIVinfected pregnant women who were part of a clinical
trial in India.14 Another study of cough of >2 weeks,
performed in Kenya by the same clinical team and by
the same ﬁrst author in a routine setting similar to the
target population for this study, failed to identify
those with TB disease (n = 187).15 The current study
differs from the earlier one in its larger sample size and
because it compares HIV-infected and non-infected
pregnant women.
Data on the utilization of symptom screening among
pregnant women in routine settings are scarce. This
has been attributed to signiﬁcant ﬁnancial and logistical challenges in the implementation of screening in
this group of patients.1 The objectives of the present
study were 1) to explore the utility of TB symptom
screening using symptoms of ⩾2 weeks’ duration in a
routine setting, and 2) to compare differences in diagnosis of TB among HIV-infected and non-infected
pregnant women in western Kenya.
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METHODS
Study design
This was a descriptive cohort study among HIV-infected
and non-infected pregnant women.

Study site and setting
The study was conducted at the Moi Teaching and Referral Hospital (MTRH) antenatal care clinic and the
AMPATH Prevention of Mother-To-Child Transmission
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(PMTCT) clinic in Eldoret, Western Kenya. The AMPATH
programme, described elsewhere, is housed by the
MTRH, which is the teaching hospital for the Moi
University School of Medicine and the second largest
referral hospital in Kenya, with the largest PMTCT
programme in western Kenya. HIV-infected pregnant
women are thus generally referred to this facility for
care, increasing the proportion of HIV-infected pregnant women at the MTRH.16–19
HIV-infected pregnant women were offered antenatal and HIV care in the AMPATH clinic, while their
non-HIV-infected counterparts were offered antenatal
care in the MTRH clinic. Both clinics are located on
the MTRH grounds in separate buildings, about 200 m
apart, and serve a similar patient population.

TB screening and management
Recommendations by the Kenya National AIDS and
STI Control Programme were to screen for TB in all
pregnant mothers at every visit. However, as no programme guidelines on how screening should be carried
out were available, screening for TB in pregnancy was
opportunistic.20 The AMPATH programme screened
both HIV-infected and non-infected patients for TB using a routine six-question symptom screening questionnaire in its cough monitor programme (Table 1).
Five years of experience among non-pregnant adult
population demonstrated a 13% sputum smear-positive
rate, with 8% of smear-negative adults positive on either culture or GeneXpert® MTB/RIF (Cepheid, Sunnyvale, CA, USA; unpublished programme data). The
Cough Monitor Programme for pregnant women was
set up within the AMPATH programme with funding
from the International Union Against Tuberculosis
and Lung Disease, Paris, France, between October 2010
and July 2012, as part of standard routine care in the
AMPATH and MTRH antenatal care clinics.
The symptom screen questionnaire was administered by cough monitors, who were lay staff trained for
this purpose. A positive response to any of the questions was regarded as a positive symptom screen, and
prompted sputum collection from those with productive cough for TB smear microscopy. The symptom
screen questionnaire was administered to each patient
only once. Patients whose microscopy and/or culture
were positive for Mycobacterium tuberculosis were offered standard anti-tuberculosis treatment per national
guidelines. The data from the symptom screen questionnaire were entered into an Excel database for programmatic use (Microsoft, Redmond, WA, USA).
When the attending clinician had a high clinical
index of suspicion for TB disease, despite unproductive
cough or sputum negative for M. tuberculosis, a shielded

TABLE 1 AMPATH symptom screening questionnaire
Cough of ⩾2 weeks
Bloody cough in the past year
Fever of ⩾3 weeks
Past history of TB diagnosis
History of TB contact in the household
Weight loss/failure to gain weight if pregnant in the past year
TB = tuberculosis.
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chest X-ray (CXR) was performed based on clinical
opinion. Based on positive CXR results or suggestive
clinical symptoms, presumptive anti-tuberculosis treatment was offered for these patients.

HIV screening and management
About 90% of pregnant women in Kenya were
screened for HIV infection as standard of care, unless
a woman opted out at the time of the study.21 Women
at the MTRH were screened according to the national
HIV screening protocol.

Population
The population included all pregnant women cared
for at the AMPATH and MTRH antenatal care clinics
from October 2010 to July 2012, who were screened
for TB using the AMPATH symptom screen questionnaire and who had clinical data captured in the cough
monitor database. Patients with unknown HIV status
and those admitted to hospital were excluded from
the analysis.

Sample size
During the study period, a total of 2983 pregnant
women received antenatal services at the AMPATH and
MTRH antenatal clinics; these women formed the
population of this study.

Data collection and data variables
Routine clinical data were collected retrospectively.
There were three sources of data in this study: the
symptom screening questionnaire database, the TB
laboratory register and patient ﬁles. The following
variables were collected from pregnant women attending the PMTCT and antenatal care clinics who
were administered the symptom screening questionnaire: age, HIV status, CD4 counts if HIV-infected, TB
symptoms per the symptom screening questionnaire,
CXR patterns, sputum obtained (yes/no) and sputum
microscopy results.

Data analysis
Data were retrieved from the cough monitor database
and evaluated for inconsistencies and missing data.
Where possible, data were corrected from source data.
Descriptive data were reported, numbers and proportions were stratiﬁed by HIV status, and continuous data
were given as median and interquartile range (IQR) for
the various subcategories related to TB symptom screening in each group.

Ethics
This study was approved by both the Institutional and
Research Ethics Committee of the MTRH, Moi University School of Medicine, Eldoret, Kenya, as well as the
Institutional Review Board of Lifespan, Providence, RI,
USA. Only de-identiﬁed data were analysed. No patient names were recorded, only patient numbers, to
enable linkage with the laboratory and patient ﬁles.
No extra data were collected outside of routine care,
and conﬁdentiality was observed at all levels of data
collection. The study was classiﬁed as an audit, and
hence of minimum risk to participants.
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TABLE 3 CXR patterns for HIV-infected pregnant women treated
presumptively for tuberculosis in western Kenya, 2010–2013
(n = 14)
Normal
Pleural effusion
Infiltrate
Milliary pattern
Other abnormalities

3
2
6
2
1

CXR = chest X-ray; HIV = human immunodeficiency virus.

FIGURE Results of TB symptom screening in pregnant women in
western Kenya, 2010–2012.

for microscopy. Of the HIV-infected and non-infected women
who had cough of ⩾2 weeks, respectively 27/43 and 15/21 had
productive cough. One non-HIV-infected patient (1/1461) was
sputum-positive; none were positive in the HIV-infected group
(Figure). The non-HIV-infected TB patient had cough, positive
history of contact with an active TB case and weight loss.
During the study period, 1% (16/1488) of the women in the
HIV-infected group were treated for TB presumptively; 14 underwent CXR and two did not. Table 3 shows the CXR features of patients treated presumptively for TB. Of the 14 patients with CXR,
10 had features suggestive of TB (pleural effusion, inﬁltrate and
miliary pattern).
During the study period, 0.6% (17/2949) of the women were
treated for TB: 16 presumptively in the HIV-infected group and
one based on a positive smear microscopy result in the non-HIVinfected group. Table 4 shows the clinical characteristics of the
patients treated for TB during the study period.

RESULTS
Of 2983 pregnant women enrolled in the study, 34 (1%) had unknown HIV status and were excluded from the analysis. Of the remaining 2949 pregnant women, 1488 (50.5%) were HIV-positive
and 1461 (49.5%) were HIV-negative (Figure). The median age of
the HIV-infected and non-HIV-infected women was respectively 30
(IQR 26–35) and 26 years (IQR 24–31). Of the HIV-infected women,
1101 had a CD4 count available; the median count at enrolment
in the PMTCT programme was 377 cells/μl (IQR 244–530).
Of the 1488 HIV-infected women, 119 (8%) had a positive TB
symptom screen, which was signiﬁcantly higher than among the
non-HIV-infected women (5%, 67/1461; P < 0.001). As regards
speciﬁc symptoms, 3% (43/1488) had a cough of ⩾2 weeks among
the HIV-infected group vs. 1% (21/1461) among the non-HIVinfected group (P = 0.014; Table 2).
Only patients with a productive cough had sputum collected

TABLE 2 TB symptoms of pregnant women who were positive on
TB symptom screen in western Kenya, 2010–2012
HIVNon-HIVinfected
infected
(n = 1488) (n = 1461)
n (%)
n (%)
Symptom screen-positive
Symptoms
Cough ⩾2 weeks
Coughed blood in the past year
Fever ⩾3 weeks
Weight loss/failure to gain weight
in the past year
Past history of TB contact in the
household
Past history of TB diagnosis

119 (8)

67 (5)

P value
<0.001

43 (3)
2 (0.1)
19 (1)

21 (1)
1 (0.1)
31 (2)

0.014
0.779
0.128

19 (1)

18 (1)

0.037

36 (2)
40 (3)

15 (1)
0

0.009
<0.001

TB = tuberculosis; HIV = human immunodeficiency virus.

DISCUSSION
In this study in western Kenya, a symptom screening questionnaire did not produce a high yield of active TB disease among
pregnant women, either HIV-infected or non-infected. Although
some women were identiﬁed using screening, the majority did
not have cough with sputum and could not be evaluated using
microscopy. CXR in this group with non-productive cough might
have revealed more positive TB cases; however, CXR was not performed systematically. Most of the cases treated were thus based
on CXR ﬁndings, demonstrating a need for further evaluation of
this test in pregnant women. Reliance on sputum microscopy
did not seem to be useful given the low sputum availability.
There seemed to be little difference in results for HIV-positive and
-negative women.
These ﬁndings are similar to previous ﬁndings in the same target population, although the earlier study had a smaller sample

TABLE 4 Clinical characteristics of pregnant women treated for TB
in western Kenya, 2010–2013 (n = 17)
Age, years, median [IQR]
Positive symptom screen
Symptoms
Cough ⩾2 weeks
Coughed blood in the past year
Productive cough
Fever ⩾3 weeks
Weight loss/failure to gain weight in past year
Past history of TB contact in the household
Past history of TB diagnosis
CD4 counts, cells/μl, median [IQR]*

30 [27–33]
4
4
1
4
1
2
2
0
256 [106–302]

* 1 non-HIV-infected patient.
TB = tuberculosis; IQR = interquartile range; HIV = human immunodeficiency virus.
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size (n = 187).15 The ﬁndings are surprising, given the fact that
Kenya is a high burden setting for HIV and TB, with an HIV prevalence of 6.2%, and ranks thirteenth among the 22 high TB burden countries globally.7,22 Of the 17 pregnant women treated for
TB, only one had a positive smear microscopy result. The large
number of patients reporting unproductive cough, particularly in
the HIV-infected group, raises concerns that TB diagnosis was perhaps being missed in this population, as sputum microscopy remains the major diagnostic testing strategy.
These ﬁndings could be attributed to the following ﬁve possibilities: 1) the TB symptom screening tool is not sensitive enough
during pregnancy. In a study in South Africa that documented a
high prevalence of TB among HIV-infected women (47/1415,
3.3%), the majority (73%) did not report any TB symptoms.23
2) Symptoms may be attenuated in people living with HIV, often
yielding negative results on smear microscopy.24 Participants in
this study who were treated for TB had a lower CD4 count than
those who were not treated for TB (256 cells/μl, IQR 106–302 vs.
377 cells/μl, IQR 244–530). 3) Physiological changes associated
with pregnancy may mask the symptoms of TB.23 4) There may a
low prevalence of TB in pregnancy—this is less plausible considering TB is a major cause of non-obstetrical maternal deaths.3 5) A
combination of all of the above.
In our setting, the utility of shielded CXR in screening for TB
in pregnancy among HIV-infected women needs to be evaluated.
Of the 17 women treated for TB in this study, 10 had CXR features suggestive of TB. Of particular note are two cases who had a
miliary pattern. This ﬁnding is consistent with previous ﬁndings
in the same population, where 10/187 patients were presumptively treated for TB based on suggestive CXR, three of whom had
a miliary pattern.15 However, a study in India demonstrated marginal to no added value of CXR in this group.14
Our study had three major limitations. First, a gold standard
for TB diagnosis was lacking, and not all patients underwent culture for TB, CXR or further evaluation other than clinical examination. Second, the WHO TB symptom screening protocol of
current cough of any duration, fever, weight loss or night sweats
was not used because the routine data analysed was from before
implementation of the WHO recommendation. Third, data on
antiretroviral use among HIV-positive participants were not collected. However, our large sample size, the fact that MTRH is a
referral hospital, which meant that our study had an equal proportion of HIV-negative and -positive participants, and the fact
that this was carried out under routine programme conditions,
are of value.

CONCLUSION
This study does not seem to demonstrate the utility of TB symptom screening questionnaires in routine settings among pregnant
women in Western Kenya. There may, however, be a role of CXR
in screening for TB among HIV-infected pregnant women. More
analytical hypothesis-driven studies need to be developed to determine the best screening tool for TB in pregnancy in high HIVTB burden, low-resource settings.
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Objective : 1) Explorer l’utilité du dépistage des symptômes de tuberculose (TB) en utilisant les symptômes d’une durée de ⩾2 semaines dans un contexte de routine, et 2) comparer les différences
en matière de diagnostic de TB entre les femmes enceintes infectées
ou non par le virus de l’immunodéficience humaine (VIH) dans
l’Ouest du Kenya.
Schéma : Etude transversale comparative chez les femmes enceintes
dont le statut VIH est connu et dépistées pour TB de 2010 à 2012 à
Eldoret, Ouest du Kenya.
Résultats : Sur 2983 participantes, respectivement 34 (1%), 1488
(50,5%) et 1461 (49,5%) avaient un statut VIH inconnu, positif et négatif. L’âge médian en années est de 30 (IQR 26–35) et de 26 (IQR
24–31), respectivement, chez les infectées et les non-infectées par le
VIH. On a trouvé un dépistage positif sur symptômes respectivement

chez 8% (119/1488) et 5% (67/1461) chez les infectées et non infectées. Le décompte médian de CD4 lors du recrutement a été de
377 cellules/μl (IQR 244–530) pour les femmes infectées par le VIH.
Chez une patiente non-infectée par le VIH, l’examen microscopique
des crachats à la recherche de la TB a été positif. Pour les femmes infectées par le VIH, la TB a été traitée sur présomption dans 1% (16/
1488) en se basant sur les symptômes cliniques et le cliché thoracique.
De manière cumulative, un traitement pour la TB a été offert à 0,6%
(17/2949) des participantes.
Conclusion : Cette étude ne semble pas démontrer l’utilité d’un questionnaire sur symptômes pour le dépistage de la TB dans un contexte
de routine parmi les femmes enceintes, qu’elles soient ou non infectées par le VIH dans l’Ouest du Kenya.

Objetivos: 1) Explorar la utilidad del cribado sistemático de los síntomas de tuberculosis (TB) en la práctica ordinaria, con base en los síntomas de ⩾2 semanas de duración; y 2) comparar las diferencias en
el diagnóstico de la TB en las embarazadas que presentan infección
por el virus de la inmunodeficiencia humana (VIH) y las embarazadas
exentas de esta infección en Kenia occidental.
Métodos: Fue este un estudio transversal comparativo de las embarazadas con situación conocida frente al VIH, a quienes se administró un cuestionario de cribado de síntomas de TB entre el 2010 y el
2012, en Eldoret en Kenia occidental.
Resultados: De 2983 participantes, 34 mujeres desconocían su situación frente al VIH (1%), 1488 eran positivas al VIH (50,5%) y 1461
eran negativas (49,5%). La mediana de la edad fue 30 años (IQR 26–
35) en las mujeres positivas al VIH y 26 años (IQR 24–31) en las mujeres sin infección por el virus. Se obtuvo un cribado positivo de sín-

tomas en 8% de las mujeres infectadas por el VIH (IQR 119–1488) y
en 5% de las mujeres sin infección (IQR 67–1461). La mediana del recuento de células CD4 en el momento del ingreso al estudio fue 377
células/μl en las mujeres infectadas por el VIH (IQR 244–530). Una
mujer negativa para el VIH presentó una baciloscopia de esputo positiva. En el grupo de mujeres infectadas por el VIH se practicó el tratamiento por presunción de TB en 1% de los casos (16/1488) con base
en los síntomas clínicos y la radiografía de tórax. Durante el estudio
se ofreció tratamiento antituberculoso a 0,6% de las participantes
(17/2949).
Conclusión: Los resultados del presente estudio no parecen demostrar la utilidad del cuestionario de cribado de síntomas de TB en la
práctica corriente de atención a las embarazadas, que presenten infección por el VIH o que estén exentas de la infección, en Kenia
occidental.
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